Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Medical Oncology (Northwood, London, England)|November 27, 2018
Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysisSakae Konishi, Shingo Hatakeyama, Toshiaki Tanaka, et al.
International Journal of Clinical Oncology|July 29, 2017
Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cavaYoshimi Tanaka, Shingo Hatakeyama, Shogo Hosogoe, et al.
The Prostate|October 31, 2022
Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective studyTakuya Oishi, Shingo Hatakeyama, Ryuji Tabata, et al.
BJUI Compass|April 27, 2022
Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancerYuki Miura, Shingo Hatakeyama, Toshikazu Tanaka, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 2, 2023
Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective studyYoshiharu Okuyama, Shingo Hatakeyama, Ryuji Tabata, et al.
BMC Cancer|May 26, 2021
Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective studyTeppei Okamoto, Daisuke Noro, Shingo Hatakeyama, et al.
BJUI Compass|April 27, 2022
Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinomaYoshiharu Okuyama, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 7, 2020
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective studyToshikazu Tanaka, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Clinical Oncology|October 17, 2020
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective studyKoichi Kido, Shingo Hatakeyama, Kazuyuki Numakura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 26, 2019
C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinomaSakae Konishi, Shingo Hatakeyama, Toshiaki Tanaka, et al.
Pageof 16